IL-STATS
25.7.2017 09:32:10 CEST | Business Wire | Press release
STATS, the global leader in sports data and intelligence, has launched an innovative new product, STATS Edge. STATS Edge is a search and analytics application powered by artificial intelligence that enables football teams to instantly find video clips and analyse complex patterns in a game with more speed and accuracy than ever before. With the power of AI-driven analytics at their fingertips, analysts can instantly and effectively assess in detail a team’s strengths and weaknesses while focusing on various aspects of the game.
Drawing on STATS’ rich history in data collection and analysis, STATS Edge will utilise data from the Premier League, Championship, La Liga, Ligue de Football Professionnel, Serie A, Bundesliga, Qatar Stars League, Champions League and more. STATS Edge will initially be available in five languages.
STATS Edge unifies football data and video through an easy-to-use and intuitive user interface, developed in close partnership with top English, French and Spanish clubs through a design-thinking methodology. This allows everyone in the football club – from match analysts to the manager – to analyse, annotate and share insights on the same platform.
“It’s increasingly difficult for clubs to process and analyse all the relevant data points available and distil complex information into timely, accurate insight,” said Kenneth Fuchs, STATS’ CEO. “On top of that, traditional analytics don’t always speak the visual language of players and coaches. We’ve applied computer vision and artificial intelligence to bring new levels of context and efficiency to teams already using video for their match preparations. It’ll save them time, allow them to develop proprietary results, and help get them the information to make, share and track the best decisions.”
The STATS Edge search engine allows managers and analysts to use their football vocabulary within a search box to find relevant video clips in seconds across entire leagues or competitions, regardless of the complexity of their queries. They can link a multitude of events and playing styles to search, which allows the execution of more than 1,000 search combinations.
The ability to search across players, teams, styles, set plays and more using natural language is a substantial step forward in accessing complex tracking data in a simple interface. For example, STATS Edge lets users quickly find and retrieve all of a team’s counter attacks which led to goals, a player’s key events such as shots or crosses in the last five games, or passes into a custom defined zone on the pitch. This use of analytics also helps clubs assess the value of a transfer target in order to reach a fully informed decision before making an investment.
Once clips are identified, STATS’ proprietary Exemplar Search, built by its award-winning data science team, can instantly find clips of similar plays at the click of a button. By using AI algorithms, the platform reads the combination of player and ball trajectories as well as events in any clip to retrieve the respective Exemplar Search results.
STATS Edge further builds on the power of AI to provide exciting and intuitive analytical features, starting with set plays and transitions. By dynamically specifying a zone on the field and other variables, the manager and analyst instantly accesses in-depth analysis and all corresponding videos. For example, in set-play analysis of an opponent, one can identify target zones and link them to the most dangerous players and their shooting or goal efficiency. In transition analysis, one can analyse the key players involved, as well as their most typical behaviour after winning or losing the ball.
About STATS
STATS is the global leader in sports intelligence. Trusted by the world’s most innovative teams, leagues and brands seeking the winning edge at the intersection of sports and technology, STATS combines the industry’s fastest and most accurate data platform with video analysis, sports content and research, player tracking through STATS SportVU®, and a range of customisable digital solutions for brands. The pioneer of live sports data, STATS continues to speed innovation in the industry today to enhance both team performance and fan experience. For more information, go to www.stats.com and follow STATS on Twitter @STATSInsightsUK .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170725005426/en/
Contact:
STATS
Dennis Dougherty, 847-583-2680
ddougherty@stats.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 03:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom